WUXI BIO: Interim Report 2025

Wuxi Bio delivered a strong performance in the first half of 2025, with revenue increasing by 16.1% year-on-year to RMB 9.95 billion; gross margin improved by 3.6 percentage points year-on-year to 42.7%. Net profit and net profit attributable to owners of the company grew by 54.8% and 56.0% year-on-year to RMB 2.76 billion and RMB 2.34 billion, respectively.During the period, the company added 86 integrated projects, bringing the total to 864. The number of preclinical and early clinical projects increased to 429 and 344, respectively, while late-stage clinical and commercial production projects reached 67 and 24, respectively. Through the execution of its 'Win-the-Molecule' strategy, the company successfully secured 9 external projects, including 2 late-stage clinical projects.The company continues to expand its global capacity footprint, with...Show More

Wuxi Bio delivered a strong performance in the first half of 2025, with revenue increasing by 16.1% year-on-year to RMB 9.95 billion; gross margin improved by 3.6 percentage points year-on-year to 42.7%. Net profit and net profit attributable to owners of the company grew by 54.8% and 56.0% year-on-year to RMB 2.76 billion and RMB 2.34 billion, respectively.During the period, the company added 86 integrated projects, bringing the total to 864. The number of preclinical and early clinical projects increased to 429 and 344, respectively, while late-stage clinical and commercial production projects reached 67 and 24, respectively. Through the execution of its 'Win-the-Molecule' strategy, the company successfully secured 9 external projects, including 2 late-stage clinical projects.The company continues to expand its global capacity footprint, with the first product from its Ireland site receiving approval from the EU EMA, and construction of the Singapore CRDMO center proceeding smoothly. Management stated that they will remain focused on enhancing their integrated platform, strengthening capacity, and promoting operational excellence through WBS lean implementation and digital initiatives, with a commitment to empowering clients in the development and delivery of innovative biopharmaceuticals.